HK1258448A1 - 診斷和治療行為障礙的方法 - Google Patents
診斷和治療行為障礙的方法Info
- Publication number
- HK1258448A1 HK1258448A1 HK19100753.6A HK19100753A HK1258448A1 HK 1258448 A1 HK1258448 A1 HK 1258448A1 HK 19100753 A HK19100753 A HK 19100753A HK 1258448 A1 HK1258448 A1 HK 1258448A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- diagnosing
- methods
- conduct disorder
- treating conduct
- treating
- Prior art date
Links
- 208000027691 Conduct disease Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562215636P | 2015-09-08 | 2015-09-08 | |
| US201562215673P | 2015-09-08 | 2015-09-08 | |
| US201562215628P | 2015-09-08 | 2015-09-08 | |
| US201562215633P | 2015-09-08 | 2015-09-08 | |
| PCT/US2016/050580 WO2017044502A1 (en) | 2015-09-08 | 2016-09-07 | Methods of diagnosing and treating conduct disorder |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1258448A1 true HK1258448A1 (zh) | 2019-11-15 |
Family
ID=56943962
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK19100753.6A HK1258448A1 (zh) | 2015-09-08 | 2019-01-16 | 診斷和治療行為障礙的方法 |
| HK19100752.7A HK1258447A1 (zh) | 2015-09-08 | 2019-01-16 | 非選擇性代謝型谷氨酸受體激活劑用於治療注意缺陷病症和22q綜合症 |
| HK19100745.7A HK1258373A1 (zh) | 2015-09-08 | 2019-01-16 | 診斷和治療圖雷特多綜合症的方法 |
| HK19100751.8A HK1258446A1 (zh) | 2015-09-08 | 2019-01-16 | 診斷和治療焦慮症的方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK19100752.7A HK1258447A1 (zh) | 2015-09-08 | 2019-01-16 | 非選擇性代謝型谷氨酸受體激活劑用於治療注意缺陷病症和22q綜合症 |
| HK19100745.7A HK1258373A1 (zh) | 2015-09-08 | 2019-01-16 | 診斷和治療圖雷特多綜合症的方法 |
| HK19100751.8A HK1258446A1 (zh) | 2015-09-08 | 2019-01-16 | 診斷和治療焦慮症的方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (12) | US11173153B2 (zh) |
| EP (9) | EP3977996B1 (zh) |
| JP (8) | JP7152306B2 (zh) |
| CN (7) | CN116919962A (zh) |
| AU (8) | AU2016318780B2 (zh) |
| CA (5) | CA2997188A1 (zh) |
| DK (4) | DK3347015T3 (zh) |
| ES (4) | ES2876898T3 (zh) |
| HK (4) | HK1258448A1 (zh) |
| IL (10) | IL290993B2 (zh) |
| SG (1) | SG10202012842SA (zh) |
| WO (4) | WO2017044503A1 (zh) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6216486B2 (ja) | 2010-08-24 | 2017-10-18 | ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアＴｈｅ Ｃｈｉｌｄｒｅｎ’Ｓ Ｈｏｓｐｉｔａｌ Ｏｆ Ｐｈｉｌａｄｅｌｐｈｉａ | 低頻度反復性遺伝的変異の注意欠陥多動性障害への関連ならびに診断および治療のためのその使用方法 |
| IL290993B2 (en) | 2015-09-08 | 2023-11-01 | Childrens Hospital Philadelphia | Methods for diagnosis and treatment of Tourette syndrome |
| WO2017210502A1 (en) * | 2016-06-03 | 2017-12-07 | Yale University | Methods and apparatus for predicting depression treatment outcomes |
| WO2018048868A1 (en) * | 2016-09-07 | 2018-03-15 | The Children's Hospital Of Philadelphia | Nonselective metabotropic glutamate receptor activators for treatment of anorexia nervosa and binge eating disorder |
| WO2018195184A1 (en) | 2017-04-19 | 2018-10-25 | Aevi Genomics Medicine, Inc. | Methods of diagnosing and treating adhd in biomarker positive subjects |
| US20200061155A1 (en) * | 2017-05-11 | 2020-02-27 | Ophidion, Inc | Compositions and methods for treating lynx2 disorders |
| CN107483425B (zh) * | 2017-08-08 | 2020-12-18 | 北京盛华安信息技术有限公司 | 基于攻击链的复合攻击检测方法 |
| TW201932453A (zh) * | 2018-01-18 | 2019-08-16 | 美商艾維基因醫學股份有限公司 | 法索西坦(fasoracetam)之固體型態 |
| KR20200135771A (ko) * | 2018-01-18 | 2020-12-03 | 더 칠드런스 호스피탈 오브 필라델피아 | 파소라세탐 결정질 형태 |
| KR102250063B1 (ko) * | 2019-06-14 | 2021-05-12 | 한국생명공학연구원 | 뚜렛증후군의 원인 유전자를 동정하는 방법 |
| CN110955751A (zh) * | 2019-11-13 | 2020-04-03 | 广州供电局有限公司 | 工作票文本去重方法、装置、系统及计算机存储介质 |
| MX2023003258A (es) * | 2020-09-21 | 2023-05-08 | Reveragen Biopharma Inc | Tratamiento de enfermedades mediadas por nf-kb. |
| WO2022065518A1 (ja) * | 2020-09-23 | 2022-03-31 | 国立大学法人京都大学 | 神経突起伸長促進剤 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004523557A (ja) | 2001-02-23 | 2004-08-05 | ジョンズ・ホプキンス・ユニバーシティ | チック、振せん、および関連疾患の治療 |
| US20050233321A1 (en) | 2001-12-20 | 2005-10-20 | Hess John W | Identification of novel polymorphic sites in the human mglur8 gene and uses thereof |
| US20070244152A1 (en) | 2004-03-25 | 2007-10-18 | Lowy Martin T | Use of an Nk3 Antagonist for the Treatment of Bipolar Disorders |
| US20100216734A1 (en) * | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| AU2007223036A1 (en) | 2006-03-08 | 2007-09-13 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| TW200819458A (en) | 2006-06-23 | 2008-05-01 | Merz Pharma Gmbh & Co Kgaa | Metabotropic glutamate receptor modulators |
| WO2008118258A2 (en) | 2007-02-06 | 2008-10-02 | Genizon Biosciences Inc. | Genemap of the human genes associated with adhd |
| US9012143B2 (en) | 2007-04-30 | 2015-04-21 | The Ohio State University Research Foundation | Polymorphisms in genes affecting ace-related disorders and uses thereof |
| US20090176740A1 (en) | 2007-11-30 | 2009-07-09 | Phillips Ii Dauglas James | Treatment of neurological conditions by the co-administration of aniracetam and l-alpha glycerylphosphorylcholine |
| WO2009105718A1 (en) | 2008-02-20 | 2009-08-27 | The Children's Hospital Of Philadelphia | Genetic alterations associated with autism and the autistic phenotype and methods of use thereof for the diagnosis and treatmemt of autism |
| WO2010057112A2 (en) | 2008-11-14 | 2010-05-20 | The Children's Hospital Of Philadelphia | Genetic variants underlying human cognition and methods of use thereof as diagnostic and therapeutic targets |
| WO2010057132A1 (en) | 2008-11-14 | 2010-05-20 | The Children's Hospital Of Philadelphia | Genetic alterations associated with schizophrenia and methods of use thereof for the diagnosis and treatment of the same |
| WO2011022312A1 (en) * | 2009-08-20 | 2011-02-24 | Merck Sharp & Dohme Corp. | Ether benzotriazole derivatives |
| US8714471B2 (en) * | 2010-07-29 | 2014-05-06 | Brady Worldwide, Inc. | Friction core brake |
| JP6216486B2 (ja) * | 2010-08-24 | 2017-10-18 | ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアＴｈｅ Ｃｈｉｌｄｒｅｎ’Ｓ Ｈｏｓｐｉｔａｌ Ｏｆ Ｐｈｉｌａｄｅｌｐｈｉａ | 低頻度反復性遺伝的変異の注意欠陥多動性障害への関連ならびに診断および治療のためのその使用方法 |
| US20130225623A1 (en) | 2010-10-27 | 2013-08-29 | Mount Sinai School Of Medicine | Methods of Treating Psychiatric or Neurological Disorders with MGLUR Antagonists |
| WO2013006857A1 (en) | 2011-07-07 | 2013-01-10 | The Children's Hospital Of Philadelphia | Genetic alterations associated with autism and the autistic phenotype and methods of use thereof for the diagnosis and treatment of autism |
| US20130143867A1 (en) * | 2011-12-02 | 2013-06-06 | Sychroneuron Inc. | Acamprosate formulations, methods of using the same, and combinations comprising the same |
| MX2015002378A (es) * | 2012-08-23 | 2015-09-25 | Stuart L Weg | Composicion ansiolitica, formulacion y metodo de uso. |
| US9346239B2 (en) | 2012-09-26 | 2016-05-24 | Eastman Kodak Company | Method for providing patterns of functional materials |
| WO2014152965A2 (en) | 2013-03-14 | 2014-09-25 | The Children's Hospital Of Philadelphia | Schizophrenia-associated genetic loci identified in genome wide association studies and use thereof as novel therapeutic targets |
| AU2015298618A1 (en) | 2014-05-30 | 2016-12-08 | The Children's Hospital Of Philadelphia | Genetic alterations associated with autism and autistic phenotype and methods of diagnosing and treating autism |
| US11219617B2 (en) | 2014-05-30 | 2022-01-11 | The Children's Hospital Of Philadelphia | Methods of diagnosing and treating autism |
| KR102232583B1 (ko) | 2015-01-08 | 2021-03-26 | 삼성전자주식회사 | 전자장치 및 전자장치의 웹 재현 방법 |
| WO2016205348A1 (en) | 2015-06-15 | 2016-12-22 | The Children's Hospital Of Philadelphia | Methods of diagnosing and treating autism |
| IL290993B2 (en) | 2015-09-08 | 2023-11-01 | Childrens Hospital Philadelphia | Methods for diagnosis and treatment of Tourette syndrome |
-
2016
- 2016-09-07 IL IL290993A patent/IL290993B2/en unknown
- 2016-09-07 IL IL300474A patent/IL300474A/en unknown
- 2016-09-07 EP EP21201628.1A patent/EP3977996B1/en active Active
- 2016-09-07 JP JP2018512234A patent/JP7152306B2/ja active Active
- 2016-09-07 CN CN202310713998.9A patent/CN116919962A/zh active Pending
- 2016-09-07 CN CN201680065071.7A patent/CN108601776A/zh active Pending
- 2016-09-07 EP EP21170586.8A patent/EP3922249B1/en active Active
- 2016-09-07 ES ES16771034T patent/ES2876898T3/es active Active
- 2016-09-07 AU AU2016318780A patent/AU2016318780B2/en active Active
- 2016-09-07 AU AU2016318785A patent/AU2016318785B2/en active Active
- 2016-09-07 US US15/258,977 patent/US11173153B2/en active Active
- 2016-09-07 CA CA2997188A patent/CA2997188A1/en active Pending
- 2016-09-07 DK DK16767115.5T patent/DK3347015T3/da active
- 2016-09-07 AU AU2016318786A patent/AU2016318786B2/en active Active
- 2016-09-07 CA CA2997191A patent/CA2997191A1/en active Pending
- 2016-09-07 ES ES16767112T patent/ES2909329T3/es active Active
- 2016-09-07 CN CN201680065020.4A patent/CN108348517B/zh active Active
- 2016-09-07 EP EP16767112.2A patent/EP3347013B1/en active Active
- 2016-09-07 CA CA2997189A patent/CA2997189A1/en active Pending
- 2016-09-07 EP EP21201653.9A patent/EP3964213B1/en active Active
- 2016-09-07 CA CA2997187A patent/CA2997187C/en active Active
- 2016-09-07 WO PCT/US2016/050581 patent/WO2017044503A1/en active Application Filing
- 2016-09-07 EP EP16767114.8A patent/EP3347014B1/en active Active
- 2016-09-07 WO PCT/US2016/050573 patent/WO2017044497A1/en active Application Filing
- 2016-09-07 WO PCT/US2016/050559 patent/WO2017044491A1/en active Application Filing
- 2016-09-07 CA CA3225374A patent/CA3225374A1/en active Pending
- 2016-09-07 CN CN202310713811.5A patent/CN116919961A/zh active Pending
- 2016-09-07 US US15/258,828 patent/US9884057B2/en active Active
- 2016-09-07 US US15/258,924 patent/US20170087139A1/en not_active Abandoned
- 2016-09-07 ES ES16767115T patent/ES2898932T3/es active Active
- 2016-09-07 CN CN202211219188.XA patent/CN115919852A/zh active Pending
- 2016-09-07 DK DK16767112.2T patent/DK3347013T3/da active
- 2016-09-07 CN CN201680065041.6A patent/CN108495630A/zh active Pending
- 2016-09-07 CN CN201680065080.6A patent/CN108348518A/zh active Pending
- 2016-09-07 DK DK16771034.2T patent/DK3347016T3/da active
- 2016-09-07 JP JP2018512253A patent/JP7281279B2/ja active Active
- 2016-09-07 JP JP2018512235A patent/JP7027308B2/ja active Active
- 2016-09-07 IL IL303605A patent/IL303605A/en unknown
- 2016-09-07 SG SG10202012842SA patent/SG10202012842SA/en unknown
- 2016-09-07 EP EP24153857.8A patent/EP4342493A2/en active Pending
- 2016-09-07 AU AU2016318775A patent/AU2016318775B2/en active Active
- 2016-09-07 JP JP2018512296A patent/JP7281280B2/ja active Active
- 2016-09-07 EP EP16771034.2A patent/EP3347016B1/en active Active
- 2016-09-07 EP EP22156141.8A patent/EP4023222A1/en active Pending
- 2016-09-07 US US15/258,969 patent/US11179378B2/en active Active
- 2016-09-07 EP EP16767115.5A patent/EP3347015B1/en active Active
- 2016-09-07 ES ES16767114T patent/ES2897953T3/es active Active
- 2016-09-07 DK DK16767114.8T patent/DK3347014T3/da active
- 2016-09-07 WO PCT/US2016/050580 patent/WO2017044502A1/en active Application Filing
-
2017
- 2017-12-21 US US15/850,307 patent/US10869861B2/en active Active
-
2018
- 2018-02-26 IL IL257744A patent/IL257744B/en unknown
- 2018-02-26 IL IL257747A patent/IL257747B/en unknown
- 2018-02-26 IL IL257746A patent/IL257746B/en unknown
- 2018-02-28 IL IL257785A patent/IL257785B/en unknown
-
2019
- 2019-01-16 HK HK19100753.6A patent/HK1258448A1/zh unknown
- 2019-01-16 HK HK19100752.7A patent/HK1258447A1/zh unknown
- 2019-01-16 HK HK19100745.7A patent/HK1258373A1/zh unknown
- 2019-01-16 HK HK19100751.8A patent/HK1258446A1/zh unknown
-
2020
- 2020-03-04 US US16/809,045 patent/US11298347B2/en active Active
- 2020-12-17 US US17/125,164 patent/US20210205288A1/en active Pending
-
2021
- 2021-10-27 US US17/511,795 patent/US11806340B2/en active Active
- 2021-10-28 US US17/512,827 patent/US11806341B2/en active Active
-
2022
- 2022-02-16 JP JP2022022123A patent/JP2022078104A/ja active Pending
- 2022-02-28 IL IL290992A patent/IL290992B2/en unknown
- 2022-02-28 IL IL290994A patent/IL290994A/en unknown
- 2022-02-28 IL IL290985A patent/IL290985A/en unknown
- 2022-04-06 US US17/714,276 patent/US20220296582A1/en active Pending
- 2022-05-05 AU AU2022203039A patent/AU2022203039A1/en active Pending
- 2022-06-20 AU AU2022204324A patent/AU2022204324A1/en active Pending
- 2022-06-21 AU AU2022204355A patent/AU2022204355A1/en active Pending
- 2022-07-11 AU AU2022205142A patent/AU2022205142A1/en active Pending
- 2022-09-29 JP JP2022155714A patent/JP2023011558A/ja active Pending
- 2022-12-09 JP JP2022197117A patent/JP2023051937A/ja active Pending
- 2022-12-09 JP JP2022197128A patent/JP2023036671A/ja active Pending
-
2023
- 2023-10-30 US US18/497,338 patent/US20240100036A1/en active Pending
- 2023-10-30 US US18/497,386 patent/US20240075022A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL290994A (en) | Methods for diagnosis and treatment of behavior disorder | |
| HK1253093A1 (zh) | 診斷和治療癌症的方法 | |
| HK1251455A1 (zh) | 聚糖治療劑和治療方法 | |
| IL285151B1 (en) | Methods for the treatment of fgf21-related disorders | |
| HK1248552A1 (zh) | 使用川地匹坦的治療方法 | |
| HK1249118A1 (zh) | 原毒素-ii變體及使用方法 | |
| HK1250476A1 (zh) | 原毒素-ii變體及使用方法 | |
| HK1251927A1 (zh) | 用於治療癌症的新穎生物標記和方法 | |
| EP3307913A4 (en) | METHOD FOR DIAGNOSIS AND TREATMENT OF AUTISM | |
| HK1249866A1 (zh) | 用他塞利昔布進行治療的方法 | |
| GB2536877B (en) | Security device and method of manufacture | |
| ZA201608306B (en) | Methods of diagnosing and treating tuberculosis | |
| SG10201702547QA (en) | Methods of vibro-treating and vibro-treating apparatus | |
| IL255012A0 (en) | Preparations and methods for treating skin conditions | |
| IL247379A0 (en) | A method for treating depression and major depressive disorder | |
| GB201503371D0 (en) | Methods of screening and treatment | |
| GB2531711B (en) | Authentication system and method of authentication | |
| GB201522615D0 (en) | Methods of screening and treatment | |
| GB201505437D0 (en) | Methods of screening and treatment | |
| GB201503392D0 (en) | Methods of screening and treatment | |
| SG11201804140PA (en) | Acidic-gas treating agent and acidic-gas treating method | |
| GB201506652D0 (en) | Method of screening and treatment | |
| GB201421511D0 (en) | Methods of screening and treatment |